In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies.
J Immunother Cancer. 2022 Mar;10(3):e004032. doi: 10.1136/jitc-2021-004032. J Immunother Cancer. 2022. PMID: 35246475 Free PMC article.